Abstract: The invention provides antisense DNA oligonucleotides which are effective in inhibiting the expression of a wild type COL1A1 gene, wherein said oligonucleotides are used in inhalation therapy to treat various lung diseases.

Abstract: The present invention concerns double-stranded NF-?B decoy oligodeoxynucleotide (NF-?B dsODN) molecules that contain a core sequence capable of specific binding to an NF-?B transcription factor. In a particular aspect, the invention concerns NF-?B decoy molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers. In another aspect, the invention concerns NF-?B decoy molecules with improved binding affinity to p65.

Abstract: Methods and compositions for reducing viral genome amounts in a target cell are provided. In the subject methods, the activity of a miRNA is inhibited in a manner sufficient to reduce the amount of viral genome in the target cell, e.g., by introducing a miRNA inhibitory agent in the target cell. Also provided are pharmaceutical compositions, kits and systems for use in practicing the subject methods. The subject invention finds use in a variety of applications, including the treatment of subjects suffering from a viral mediated disease condition, e.g., an HCV mediated disease condition.

Abstract: A method for detecting nucleic acids wherein the binding activity of a nucleic acid aptamer, which is formed by the hybridization of a target nucleotide sequence and a probe, is detected using the binding with a ligand as an index has been provided. Utilizing a structure such as the three-way junction, whose binding activity significantly changes depending on a mismatch of a single nucleotide, as the nucleic acid aptamer SNP can be detected.

Abstract: The present invention provides for a transgenic animal model that constitutively expresses a protein encoded by the NPM-ALK gene in lymphoid tissue, and exhibits enhanced and accelerated development of a T cell lymphoproliferative disorder or B cell plasma cell tumor, together with the identification of cells transduced with the ALK tyrosine kinase gene or fusion proteins thereof, and methods for using this animal model and cells for screening compounds or treatments for antitumor activity. In preferred embodiments, the animal is a transgenic mouse that expresses a human NPM-ALK gene operably linked to human regulatory sequences, and the cells of the mouse have at least one copy of the NPM-ALK transgene, whereby the mouse constitutively expresses a protein encoded by the NPM-ALK transgene. The animals and cells of the invention are useful in the study of NPM-ALK-dependent lymphomagenesis and plasma cell tumors and in the development of treatments for these conditions.

Abstract: The present invention provides novel synthetic oligonucleotide sequences (hereinafter sequence) of 3 to 9 bases in length comprising one or more non-DNA bases wherein the bases are nebularine, hypoxanthine, or uracil, or combinations of nebularine, hypoxanthine and uracil bases. These sequences optionally further comprise one or more guanine bases or one or more thymine bases, or combinations thereof. The present invention also provides methods of using these compositions to induce responses in cells, and to treat diseases and conditions characterized by undesired cellular proliferation such as autoimmune disease, lymphoproliferative disease, inflammation or cancer.

Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of tumorigenic and/or angiogenic disorders, including, but not limited to, lung tumors, breast tumors, ovary tumors, colon tumors, hemangioma, and metastatic and angiogenic tumors. The invention further provides methods for identifying a compound capable of treating a tumorigenic and/or angiogenic disorder or modulating tumorigenesis and/or angiogenesis. The invention also provides methods for modulating tumorigenesis and/or angiogenesis, e.g., modulating tumorigenesis and/or angiogenesis in a subject. In addition, the invention provides a method for treating a subject having a tumorigenic and/or angiogenic disorder characterized by aberrant 32616 polypeptide activity or aberrant 32616 nucleic acid expression.